Agios Pharmaceuticals : ENERGIZE Phase 3 Topline Results -January 03, 2024 at 08:22 am EST
Topline Results: Phase 3 ENERGIZE Study of PYRUKYND® in Thalassemia January 3, 2024 ...
Source: marketscreener.com
Page 5 - Brian Goff News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Brian Goff. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Brian Goff Today - Breaking & Trending Today
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Agios Pharmaceuticals Incorporated quarter three 2023 earnings conference call.
Source: insidermonkey.com
'We cannot afford to pay any more than we're paying now' – SMEs face perfect storm
From hikes in the minimum wage to an increase in the hospitality Vat rate, some say it’s never been harder to be in business
Source: businesspost.ie
JPMorgan Chase & Co. Trims Agios Pharmaceuticals (NASDAQ:AGIO) Target Price to $32.00
Agios Pharmaceuticals (NASDAQ:AGIO – Free Report) had its target price cut by JPMorgan Chase & Co. from $33.00 to $32.00 in a research report sent to investors on Monday morning, Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock. Several other analysts also recently issued reports on AGIO. StockNews.com downgraded Agios […]
Source: modernreaders.com
Agios Pharmaceuticals (NASDAQ:AGIO) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.51) EPS for the quarter, topping the consensus estimate of ($1.60) by $0.09, Briefing.com reports. The firm had revenue of $6.70 million during the quarter, compared to analyst estimates of $6.46 million. Agios Pharmaceuticals had a negative […]
Source: modernreaders.com